Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Pharmacological Reviews
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Pharmacological Reviews

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit Pharm Rev on Facebook
  • Follow Pharm Rev on Twitter
  • Follow ASPET on LinkedIn
Review ArticleReview Article
Open Access

Aldo-Keto Reductases and Cancer Drug Resistance

Trevor M. Penning, Sravan Jonnalagadda, Paul C. Trippier and Tea Lanišnik Rižner
Michael Gottesman, ASSOCIATE EDITOR
Pharmacological Reviews July 2021, 73 (3) 1150-1171; DOI: https://doi.org/10.1124/pharmrev.120.000122
Trevor M. Penning
Center of Excellence in Environmental Toxicology, Department of Systems Pharmacology & Translational Therapeutics, Philadelphia, Pennsylvania (T.M.P.); Department of Pharmaceutical Science (S.J., P.C.T.) and Fred and Pamela Buffett Cancer Center (P.C.T.), University of Nebraska Medical Center and UNMC Center for Drug Discovery, Omaha, Nebraska; and Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia (T.L.R.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sravan Jonnalagadda
Center of Excellence in Environmental Toxicology, Department of Systems Pharmacology & Translational Therapeutics, Philadelphia, Pennsylvania (T.M.P.); Department of Pharmaceutical Science (S.J., P.C.T.) and Fred and Pamela Buffett Cancer Center (P.C.T.), University of Nebraska Medical Center and UNMC Center for Drug Discovery, Omaha, Nebraska; and Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia (T.L.R.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul C. Trippier
Center of Excellence in Environmental Toxicology, Department of Systems Pharmacology & Translational Therapeutics, Philadelphia, Pennsylvania (T.M.P.); Department of Pharmaceutical Science (S.J., P.C.T.) and Fred and Pamela Buffett Cancer Center (P.C.T.), University of Nebraska Medical Center and UNMC Center for Drug Discovery, Omaha, Nebraska; and Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia (T.L.R.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tea Lanišnik Rižner
Center of Excellence in Environmental Toxicology, Department of Systems Pharmacology & Translational Therapeutics, Philadelphia, Pennsylvania (T.M.P.); Department of Pharmaceutical Science (S.J., P.C.T.) and Fred and Pamela Buffett Cancer Center (P.C.T.), University of Nebraska Medical Center and UNMC Center for Drug Discovery, Omaha, Nebraska; and Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia (T.L.R.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Gottesman
Roles: ASSOCIATE EDITOR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
PreviousNext
Back to top

In this issue

Pharmacological Reviews: 73 (3)
Pharmacological Reviews
Vol. 73, Issue 3
1 Jul 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Pharmacological Reviews article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Aldo-Keto Reductases and Cancer Drug Resistance
(Your Name) has forwarded a page to you from Pharmacological Reviews
(Your Name) thought you would be interested in this article in Pharmacological Reviews.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Review ArticleReview Article

Aldo-Keto Reductases and Cancer Drug Resistance

Trevor M. Penning, Sravan Jonnalagadda, Paul C. Trippier and Tea Lanišnik Rižner
Pharmacological Reviews July 1, 2021, 73 (3) 1150-1171; DOI: https://doi.org/10.1124/pharmrev.120.000122

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Review ArticleReview Article

Aldo-Keto Reductases and Cancer Drug Resistance

Trevor M. Penning, Sravan Jonnalagadda, Paul C. Trippier and Tea Lanišnik Rižner
Pharmacological Reviews July 1, 2021, 73 (3) 1150-1171; DOI: https://doi.org/10.1124/pharmrev.120.000122
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Visual Overview
    • Abstract
    • I. Introduction to Aldo-Keto Reductases
    • II. Stress Response and Nuclear Factor-Erythroid 2 p45-Related Factor 2 Induction of Aldo-Keto Reductases
    • III. Somatic Mutations and Epigenetic Regulation of the Nuclear Factor-Erythroid 2 p45-Related Factor 2-Kelch-Like ECH-Associated Protein 1 Pathway
    • IV. Resistance to Major Cancer Chemotherapeutics Mediated by Aldo-Keto Reductases
    • V. Resistance to Antihormonal Therapies Mediated by Aldo-Keto Reductases
    • VI. Inactivators of the Nuclear Factor-Erythroid 2 p45-Related Factor 2-Kelch-Like ECH-Associated Protein 1 System
    • VII. Inhibitors of Aldo-Keto Reductases to Surmount Drug Resistance
    • VIII. Inhibitors of Aldo-Keto Reductases to Potentiate the Effects of Chemotherapeutic Agents
    • IX. Resistance Versus Disease Progression: Cause or Consequence
    • X. Clinical Use of Nuclear Factor-Erythroid 2 p45-Related Factor 2 and AKR Inhibitors to Surmount Chemotherapeutic Drug Resistance
    • XI. Conclusions
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Quantitative Proteomics in Translational Pharmacokinetics
  • Adenosine in Cancer
  • Molecular Mechanisms of CO-Mediated Signaling
Show more Review article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Pharmacological Reviews
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacology Research & Perspectives
ISSN 1521-0081 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics